Ignite Creation Date:
2024-05-05 @ 6:45 PM
Last Modification Date:
2024-10-26 @ 9:37 AM
Study NCT ID:
NCT00546156
Status:
COMPLETED
Last Update Posted:
2021-05-18
First Post:
2007-10-17
Brief Title:
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
Sponsor:
Ian E Krop MD PhD
Organization:
Dana-Farber Cancer Institute
Organization Data
Organization:
Dana-Farber Cancer Institute
Class:
OTHER
Study ID:
07-130
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Ian E Krop MD PhD
Lead Sponsor Class:
OTHER
Responsible Party:
Ian E Krop MD PhD
Responsible Party Title:
Medical Oncologist
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Dana-Farber Cancer Institute
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Genentech Inc | INDUSTRY |
| Massachusetts General Hospital | OTHER |
| Brigham and Womens Hospital | OTHER |
| New Hampshire Oncology-Hematology PA | UNKNOWN |